Bibliography
- Garnier JP. Rebuilding the R&D engine in big pharma. Harv Bus Rev 2008;86:68-6,128
- Eichler HG, Pignatti F, Flamion B, et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 2008;7:818-26
- Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-36
- Available from: http://www.theheart.org/article/908435.do
- Kontush A, Guerin M, Chapman MJ. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008;5:329-36
- deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008;51:2199-211
- Singh U, Devaraj S, Jialal I, et al. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008;102:321-5
- Duivenvoorden R, Nederveen AJ, de GE, et al. Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs. Curr Opin Lipidol 2007;18:613-21
- Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 2008;7:517-29
- Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
- Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008;7:807-17
- Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-31
- Ballantyne C, Cushman M, Psaty B, et al. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007;14:3-11
- Wilensky RL, Shi Y, Mohler ER III, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059-66
- Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82
- Boekholdt SM, de Winter RJ, Kastelein JJ. Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier? Circulation 2008;118:1120-2
- Suckling K. The landscape of drug discovery in atherosclerosis and dyslipidaemia: a survey from patenting activity. Expert Opin Ther Patents 2008;18:473-84